Bioline Reagents (UK; part of Meridian Bioscience, Inc.) has signed an exclusive distribution agreement with Alliance Global to bring their high quality molecular biology portfolio to AGBL’s customers.
“Bioline’s diverse molecular biology and PCR reagents will complement the AGBL range of products and further support our customers in the academic, environmental and industrial markets.” said Fatima Kakal, Product Manager Cell and Molecular Biology Division at Alliance Global Group.
Statement by Andre
” Establishing this exciting partnership with AGBL enables the highly-respected Bioline brand to penetrate further into the Middle East, Africa and Central Asia Bioline’s high performance products are an excellent fit for AGBL and will offer their end users some of the best molecular biology solutions available.”
-Ends-
About Bioline Reagents
Bioline
Founded in 1992 and headquartered in London, UK, Bioline is an evolving international company and our mission is to provide customers with a range of products which are fast and easy to use, guaranteed to work and developed by scientists who understand what our customers are trying to achieve so they can focus on their scientific goals. At Bioline, we constantly strive to improve and to deliver high quality products which are the result of our strong commitment and investment in science. Bioline, wholly owned by Meridian Bioscience Inc. (Nasdaq: VIVO), operates as one multi-cultural global team with strong values.
Bioline is an ISO 13485 certified company and one of the world’s few manufacturers of ultra-pure dNTPs, as well as a variety of enzymes and biochemicals.
For more information please visit: www.bioline.com
About Alliance Global Group (AGBL)
The AGBL Group of companies is the largest biomedical gateway to the emerging markets of the Middle East, Africa and Asia. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic users in the emerging healthcare markets within the MEAA region. The group's stated mission is to improve the lives of the region's inhabitants through novel biomedical technologies and products. For more information, please visit: www.agbl.net
Forward-Looking Statements
All statements in this press release that are not historical and are forward-looking statements, including, among other things, statements relating to future uses, quality or performance of, or benefits of using, products or technologies, the expected benefits of the agreement between AGBL and Bioline and other future events.
AGBL undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
